Overview

SSR240600C Treatment in Women With Overactive Bladder

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Tolterodine Tartrate